Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID 73 EV-to-EBIT is 17.02 as of Sep. 06, 2026, which is 26% below its 10-year median of 22.99. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT769.84 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Pharma Aids ranks better than 54.11% on this metric.
The historical rank and industry rank for Pharma Aids's EV-to-EBIT or its related term are showing as below:
DHA:PHARMAID'
s EV-to-EBIT Range Over the Past 10 Years
Min: 15.55 Med: 22.99 Max: 5122.01
Current: 17.02
During the past 13 years, the highest EV-to-EBIT of Pharma Aids was 5122.01. The lowest was 15.55. And the median was 22.99.
DHA:PHARMAID's EV-to-EBIT is ranked better than 54.11% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.52
vs DHA:PHARMAID: 17.02
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pharma Aids's Enterprise Value for the quarter that ended in Mar. 2026 was BDT1,650.1 Mil.
Pharma Aids's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT104.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids EV-to-EBIT Related Terms
Pharma Aids EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pharma Aids's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:PHARMAID vs ISRG, BDX, RMD: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pharma Aids's EV-to-EBIT falls into.
Pharma Aids's current Enterprise Value is BDT1,775.2 Mil.
Pharma Aids's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT104.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids (DHA:PHARMAID) has a EV-to-EBIT of 17.02 as of Sep. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma Aids and its competitors. This is 26% below median its historical median of 22.99. Over the past decade, Pharma Aids' EV-to-EBIT has ranged from 15.55 to 5,122.01. According to the industry distribution chart, Pharma Aids ranks #218 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 45.9%.
Is Pharma Aids' EV-to-EBIT too high?
Pharma Aids' current EV-to-EBIT of 17.02 is 26% below median its 10-year median of 22.99. Over the past 10 years, this metric has ranged from a low of 15.55 to a high of 5,122.01. The Medical Devices & Instruments industry median EV-to-EBIT is 18.52. Pharma Aids' value of 17.02 is 8.1% below this industry median. Based on the distribution chart, Pharma Aids ranks #218 out of 475 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #218 out of 475 companies for EV-to-EBIT. This puts Pharma Aids in the upper half of its industry. The industry median EV-to-EBIT is 18.52. Pharma Aids' value of 17.02 is 8.1% below this benchmark. Historically, Pharma Aids' own EV-to-EBIT has ranged from 15.55 to 5,122.01 over the past decade. While the company's 10-year median is 22.99 vs. the industry median of 18.52, Pharma Aids has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.52, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current EV-to-EBIT of 17.02 is 8.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pharma Aids and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current EV-to-EBIT is 17.02, which is 26% below median its own 10-year median of 22.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT769.84, compared to a current price of BDT576.00 — trading 25.2% below its estimated fair value. The current EV-to-EBIT is 17.02, which is 26% below median its 10-year median of 22.99 and 8.1% below the Medical Devices & Instruments industry median of 18.52. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current EV-to-EBIT is 17.02 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT576.00 is trading 25.2% below its estimated GF Value™ of BDT769.84.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
EV-to-EBIT: 17.02 (26% below median its 10-year median of 22.99)
GF Value™: BDT769.84 vs. price of BDT576.00 (25.2% below fair value)
Industry Position: 8.1% below the Medical Devices & Instruments median (#218 of 475)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
